Idorsia posts investor presentation outlining QUVIVIQ growth strategy

PUBT · 2d ago
Idorsia posts investor presentation outlining QUVIVIQ growth strategy
  • Idorsia reaffirmed full-year 2026 guidance for Idorsia-led QUVIVIQ sales of CHF 200 million.
  • Non-GAAP EBIT guidance kept at CHF -120 million; US-GAAP EBIT guidance maintained at CHF -160 million.
  • H1 2026 Idorsia-led QUVIVIQ sales totaled CHF 91 million; US QUVIVIQ sales returned to growth, reaching CHF 9.3 million in Q2 2026.
  • Roland Wandeler will join as CEO on Oct. 1, 2026.
  • Financing included a CHF 250 million facility from Pharmakon; total liquidity at June 30, 2026 was CHF 189 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.